The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Robust neutralizing antibodies to SARS-CoV-2 infection persist for months
Open accessPublished version of a preprint
Abstract
SARS-CoV-2 antibodies persist: As the number of daily COVID-19 cases continues to mount worldwide, the nature of the humoral immune response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains uncertain. Wajnberg et al. used a cohort of more than 30,000 infected individuals with mild to moderate COVID-19 symptoms to determine the robustness and longevity of the anti–SARS-CoV-2 antibody response. They found that neutralizing antibody titers against the SARS-CoV-2 spike protein persisted for at least 5 months after infection. Although continued monitoring of this cohort will be needed to confirm the longevity and potency of this response, these preliminary results suggest that the chance of reinfection may be lower than is currently feared. Science , this issue p. 1227
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, given the relatively small size of some of these cohorts and the lack of systematic SARS-CoV-2 molecular testing, the true population effect remains unknown.”
In the citing paper
“More than 90% of individuals infected with SARS-CoV-2 develop antibodies about 1 week after symptom onset, persisting for at least 3 months.”
In the citing paper
“A few studies to date have reported that individuals with SARS-CoV-2 antibodies are at lower risk of clinical reinfection than are antibody-negative individuals.”
In the citing paper
“Although the exact length of immunity conferred by natural infection is still unknown, titres of neutralising antibodies against the SARS-CoV-2 spike protein were detectable for at least 5 months after primary infection.”
In the citing paper
“SARS-CoV-2 infection can induce the production of neutralizing antibodies, and these antibodies are believed to contribute to protection from reinfection (Rodda et al., 2020; Wajnberg et al., 2020).”
From SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies (2021) · cites this paper as Wajnberg et al., 2020
In the citing paper
“However, it should also be noted that circulating SARS-CoV-2 neutralizing antibody titers are relatively low in a substantial fraction of recovered COVID-19 cases (Dan et al., 2021; Robbiani et al., 2020; Wajnberg et al., 2020), indicating that either the neutralizing antibody potency or the serum concentration is suboptimal in this subset.”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Wajnberg et al., 2020
In the citing paper
“circulating SARS-CoV-2 IgG titers are well maintained for 3–4 months (Gudbjartsson et al., 2020; Wajnberg et al., 2020).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Wajnberg et al., 2020
In the citing paper
“data so far indicate that T cell memory, B cell memory, and antibodies are all likely to persist for years in most individuals infected by SARS-CoV-2 (Dan et al., 2021; Gaebler et al., 2020; Wajnberg et al., 2020; Zuo et al., 2020a).”
From Adaptive immunity to SARS-CoV-2 and COVID-19 (2021) · cites this paper as Wajnberg et al., 2020
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Letko, M., Marzi, A., & Munster, V. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0688-y · Cited by 3,109
Antibody responses to SARS-CoV-2 in patients with COVID-19
Long, Q.-X., Liu, B.-Z., Deng, H.-J., Wu, G.-C., Deng, K., Chen, Y.-K., Liao, P., Qiu, J.-F., Lin, Y., Cai, X.-F., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0897-1 · Cited by 2,876
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686
A serological assay to detect SARS-CoV-2 seroconversion in humans
Amanat, F., Stadlbauer, D., Strohmeier, S., Nguyen, T. H. O., Chromikova, V., McMahon, M., Jiang, K., Arunkumar, G. A., Jurczyszak, D., Polanco, J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0913-5 · Cited by 1,769
Self-citationCorrelates of protection induced by vaccination
Plotkin, S. A. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00131-10 · Cited by 1,745
A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2
Shi, R., Shan, C., Duan, X., Chen, Z., Liu, P., Song, J., Song, T., Bi, X., Han, C., Wu, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2381-y · Cited by 1,286
SARS-CoV-2 Vaccines: Status Report
Amanat, F., & Krammer, F. (2020) · Immunity · doi:10.1016/j.immuni.2020.03.007 · Cited by 1,120
Self-citationHuang, A. T., Garcia-Carreras, B., Hitchings, M. D. T., Yang, B., Katzelnick, L. C., Rattigan, S. M., Borgert, B. A., Moreno, C. A., Solomon, B. D., Trimmer-Smith, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18450-4 · Cited by 1,026
DNA vaccine protection against SARS-CoV-2 in rhesus macaques
Yu, J., Tostanoski, L. H., Peter, L., Mercado, N. B., McMahan, K., Mahrokhian, S. H., Nkolola, J. P., Liu, J., Li, Z., Chandrashekar, A., et al. (2020) · Science · doi:10.1126/science.abc6284 · Cited by 997
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 1,007
The scientific and ethical feasibility of immunity passports
Brown, R. C. H., Kelly, D. F., Wilkinson, D. J. C., & Savulescu, J. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30766-0 · Cited by 136
COVID-19 vaccines for patients with cancer: benefits likely outweigh risks
Hwang, J. K., Zhang, T., Wang, A. Z., & Li, Z. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01046-w · Cited by 127
A look into the future of the COVID-19 pandemic in Europe: an expert consultation
Iftekhar, E. N., Priesemann, V., Balling, R., Bauer, S., Beutels, P., Valdez, A. C., Cuschieri, S., Czypionka, T., Dumpis, U., Glaab, E., et al. (2021) · The Lancet Regional Health - Europe · doi:10.1016/j.lanepe.2021.100185 · Cited by 132
Ghorbani, S. S., Taherpour, N., Bayat, S., Ghajari, H., Mohseni, P., & Nazari, S. S. H. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27281 · Cited by 131
SARS-CoV-2 mediated neuroinflammation and the impact of COVID-19 in neurological disorders
Amruta, N., Chastain, W. H., Paz, M., Solch-Ottaiano, R. J., Murray-Brown, I. C., Befeler, J. B., Gressett, T. E., Longo, M. T., Engler-Chiurazzi, E. B., & Bix, G. J. (2021) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2021.02.002 · Cited by 123
Immunological memory to SARS-CoV-2 assessed for up to eight months after infection.
Dan, J. M., Mateus, J., Kato, Y., Hastie, K. M., Yu, E. D., Faliti, C. E., Grifoni, A., Ramirez, S. I., Haupt, S., Frazier, A., et al. (2020) · eScholarship (California Digital Library) · Cited by 121
Self-citationDoes infection with or vaccination against SARS-CoV-2 lead to lasting immunity?
Milne, G., Hames, T., Scotton, C. J., Gent, N., Johnsen, A., Anderson, R. M., & Ward, T. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00407-0 · Cited by 123
SARS-CoV-2 spike protein: a key target for eliciting persistent neutralizing antibodies
Yang, Y., & Du, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00523-5 · Cited by 118
Antibody-dependent cellular cytotoxicity response to SARS-CoV-2 in COVID-19 patients
Yu, Y., Wang, M., Zhang, X., Li, S., Lu, Q., Zeng, H., Hou, H., Li, H., Zhang, M., Jiang, F., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00759-1 · Cited by 122
Vaccines and allergic reactions: The past, the current COVID‐19 pandemic, and future perspectives
Sampath, V., Rabinowitz, G., Shah, M. M., Jain, S., Diamant, Z., Jeseňák, M., Rabin, R. L., Vieths, S., Agache, I. O., Akdiş, M., et al. (2021) · Allergy · doi:10.1111/all.14840 · Cited by 117
Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis
Thye, A. Y.-K., Law, J. W., Pusparajah, P., Letchumanan, V., Chan, K., & Lee, L. (2021) · Biomedicines · doi:10.3390/biomedicines9101303 · Cited by 121
Gangaev, A., Ketelaars, S. L. C., Isaeva, O. I., Patiwael, S., Dopler, A., Hoefakker, K., De Biasi, S., Gibellini, L., Mussini, C., Guaraldi, G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22811-y · Cited by 111
Kapłonek, P., Fischinger, S., Cizmeci, D., Bartsch, Y. C., Kang, J., Burke, J. S., Shin, S. A., Dayal, D., Martin, P., Mann, C. J., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.01.001 · Cited by 121
Self-citationReinfection With SARS-CoV-2: Implications for Vaccines
Cohen, J. I., & Burbelo, P. D. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1866 · Cited by 111
Yang, Y., Yang, M., Peng, Y., Liang, Y., Wei, J., Xing, L., Guo, L., Li, X., Li, J., Wang, J., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-021-01051-2 · Cited by 111
Cady, N. C., Tokranova, N. A., Minor, A., Nikvand, N., Strle, K., Lee, W. T., Page, W. D., Guignon, E., Pilar, A., & Gibson, G. N. (2020) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2020.112679 · Cited by 109
Antibody Responses 8 Months after Asymptomatic or Mild SARS-CoV-2 Infection
Choe, P. G., Kim, K., Kang, C. K., Suh, H. J., Kang, E., Lee, S. Y., Kim, N. J., Yi, J., Park, W. B., & Oh, M. (2020) · Emerging infectious diseases · doi:10.3201/eid2703.204543 · Cited by 111
Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV
Alrubayyi, A., Gea‐Mallorquí, E., Touizer, E., Hameiri‐Bowen, D., Kopycinski, J. T., Charlton, B. G., Fisher-Pearson, N., Muir, L., Rosa, A., Roustan, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26137-7 · Cited by 107
Alfego, D., Sullivan, A., Poirier, B., Williams, J., Grover, A., Gillim, L., Adcock, D. M., & Letovsky, S. I. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100902 · Cited by 104
Stable neutralizing antibody levels 6 months after mild and severe COVID-19 episodes
Pradenas, E., Trinité, B., Urrea, V., Marfil, S., Ávila‐Nieto, C., de la Concepción, M. L. R., Tarrés-Freixas, F., Pérez-Yanes, S., Rovirosa, C., Ainsua‐Enrich, E., et al. (2021) · Med · doi:10.1016/j.medj.2021.01.005 · Cited by 106
Dupont, L., Snell, L. B., Graham, C., Seow, J., Merrick, B., Lechmere, T., Maguire, T. J. A., Hallett, S. R., Pickering, S., Charalampous, T., et al. (2021) · Nature Microbiology · doi:10.1038/s41564-021-00974-0 · Cited by 102
The immunology of SARS-CoV-2 infections and vaccines
Grigoryan, L., & Pulendran, B. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101422 · Cited by 102
Aziz, N. A., Corman, V. M., Echterhoff, A. K. C., Müller, M. A., Richter, A. M., Schmandke, A., Schmidt, M. L., Schmidt, T. H., de Vries, F. M., Drosten, C., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22351-5 · Cited by 107
Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies
Alenquer, M., Ferreira, F., Lousa, D., Valério, M., Medina-Lopes, M., Bergman, M., Gonçalves, J., Demengeot, J., Leite, R. B., Lilue, J., et al. (2021) · PLoS Pathogens · doi:10.1371/journal.ppat.1009772 · Cited by 101
Fröberg, J., Gillard, J., Philipsen, R. L. A., Lanke, K. H. W., Rust, J., van Tuijl, D., Teelen, K., Bousema, T., Simonetti, E. R., Jongh, C. E. V. D. G., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25949-x · Cited by 105
Richards, N. E., Keshavarz, B., Workman, L. J., Nelson, M. R., Platts‐Mills, T. A. E., & Wilson, J. M. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.24331 · Cited by 98
Jeremijenko, A., Chemaitelly, H., Ayoub, H. H., Alishaq, M., Abou-Samra, A.-B., Al Ajmi, J. A. A. A., Al Ansari, N. A. A., Al Kanaani, Z., Al Khal, A., Al Kuwari, E., et al. (2021) · Emerging Infectious Diseases · doi:10.3201/eid2705.204365 · Cited by 97
Comparison of Seroconversion in Children and Adults With Mild COVID-19
Toh, Z. Q., Anderson, J., Mazarakis, N., Neeland, M. R., Higgins, R. A., Rautenbacher, K., Dohle, K., Nguyen, J., Overmars, I., Donato, C. M., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.1313 · Cited by 102
Sun, D., Sang, Z., Kim, Y. J., Xiang, Y., Cohen, T., Belford, A. K., Huet, A., Conway, J. F., Sun, J., Taylor, D. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24963-3 · Cited by 96
Hall, V. J., Foulkes, S., Charlett, A., Atti, A., Monk, E., Simmons, R., Wellington, E., Cole, M., Saei, A., Oguti, B., et al. (2021) · medRxiv · doi:10.1101/2021.01.13.21249642 · Cited by 100
Loss of Anti–SARS-CoV-2 Antibodies in Mild Covid-19
Bölke, E., Matuschek, C., & Fischer, J. C. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2027051 · Cited by 95
Sun, W., McCroskery, S., Liu, W., Leist, S. R., Liu, Y., Albrecht, R. A., Slamanig, S., Oliva, J., Amanat, F., Schäfer, A., et al. (2020) · Vaccines · doi:10.3390/vaccines8040771 · Cited by 95
Self-citationB-cell and antibody responses to SARS-CoV-2: infection, vaccination, and hybrid immunity
Lapuente, D., Winkler, T., & Tenbusch, M. (2023) · Cellular and Molecular Immunology · doi:10.1038/s41423-023-01095-w · Cited by 101
Durable SARS-CoV-2 B cell immunity after mild or severe disease
Ogega, C. O., Skinner, N., Blair, P. W., Park, H.-S., Littlefield, K. E., Ganesan, A., Dhakal, S., Ladiwala, P., Antar, A. A. R., Ray, S. C., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci145516 · Cited by 91
SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization
Hoffmann, M., Zhang, L., Krüger, N., Graichen, L., Kleine‐Weber, H., Hofmann-Winkler, H., Kempf, A. M., Nessler, S., Riggert, J., Winkler, M. S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109017 · Cited by 94
Grzelak, L., Velay, A., Madec, Y., Gallais, F., Staropoli, I., Schmidt‐Mutter, C., Wendling, M.-J., Meyer, N., Planchais, C., Rey, D., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab127 · Cited by 90
Persistence of neutralizing antibodies a year after SARS‐CoV‐2 infection in humans
Haveri, A., Ekström, N., Solastie, A., Virta, C., Österlund, P., Isosaari, E., Nohynek, H., PALMU, A. A. I., & Melin, M. M. (2021) · European Journal of Immunology · doi:10.1002/eji.202149535 · Cited by 92
Muena, N. A., García‐Salum, T., Pardo‐Roa, C., Avendaño, M. J., Serrano, E. F., Lévican, J., Almonacid, L. I., Valenzuela, G. H., Poblete, E., Strohmeier, S., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.103972 · Cited by 85
Self-citationFielding, C. A., Sabberwal, P., Williamson, J. C., Greenwood, E. J. D., Crozier, T. W. M., Zelek, W. M., Seow, J., Graham, C., Huettner, I., Edgeworth, J. D., et al. (2022) · eLife · doi:10.7554/elife.74489 · Cited by 87
Xiang, T., Liang, B., Fang, Y., Lu, S., Li, S., Wang, H., Li, H., Yang, X., Shěn, S., Zhu, B., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.708523 · Cited by 84
Anand, U., Jakhmola, S., Indari, O., Jha, H. C., Chen, Z., Tripathi, V. S., & de la Lastra, J. M. P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.658519 · Cited by 84
Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2
Favresse, J., Gillot, C., Chiaro, L. D., Eucher, C., Elsen, M., Eeckhoudt, S. V., David, C., Morimont, L., Dogné, J., & Douxfils, J. (2021) · Viruses · doi:10.3390/v13071364 · Cited by 85
Point-of-care diagnostics: recent developments in a pandemic age
Harpaldas, H., Arumugam, S., Rodriguez, C. C., Kumar, B. A., Shi, V. Y., & Sia, S. K. (2021) · Lab on a Chip · doi:10.1039/d1lc00627d · Cited by 82
Murhekar, M. V., Bhatnagar, T., Thangaraj, J. W. V., Saravanakumar, V., Kumar, M. S., Selvaraju, S., Rade, K., Kumar, C. P. G., Sabarinathan, R., Turuk, A., et al. (2021) · PLoS Medicine · doi:10.1371/journal.pmed.1003877 · Cited by 81
Immunity to SARS-CoV-2 up to 15 months after infection
Marcotte, H., Piralla, A., Zuo, F., Du, L., Cassaniti, I., Wan, H., Kumagai‐Braesch, M., Andréll, J., Percivalle, E., Sammartino, J. C., et al. (2022) · iScience · doi:10.1016/j.isci.2022.103743 · Cited by 83
Development and deployment of COVID-19 vaccines for those most vulnerable
Koff, W. C., Schenkelberg, T., Williams, T. M., Baric, R. S., McDermott, A. B., Cameron, C., Cameron, M. J., Frieman, M. B., Neumann, G., Kawaoka, Y., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abd1525 · Cited by 80
Decay of Fc-dependent antibody functions after mild to moderate COVID-19
Lee, W. S., Selva, K. J., Davis, S. K., Wines, B. D., Reynaldi, A., Esterbauer, R., Kelly, H. G., Haycroft, E. R., Tan, H., Juno, J. A., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100296 · Cited by 81
Primary, Recall, and Decay Kinetics of SARS-CoV-2 Vaccine Antibody Responses
Ibarrondo, F. J., Hofmann, C., Fulcher, J. A., Goodman‐Meza, D., Mu, W., Hausner, M. A., Ali, A., Balamurugan, A., Taus, E., Elliott, J. E., et al. (2021) · ACS Nano · doi:10.1021/acsnano.1c03972 · Cited by 79
Machado, B. A. S., Hodel, K. V. S., Júnior, V. G. B., Soares, M. B. P., & Badaró, R. J. D. S. (2020) · Viruses · doi:10.3390/v13010040 · Cited by 77
Lockdowns and the COVID-19 pandemic: What is the endgame?
Lytras, T., & Tsiodras, S. (2020) · Scandinavian Journal of Public Health · doi:10.1177/1403494820961293 · Cited by 82
Shioda, K., Lau, M. S. Y., Kraay, A. N. M., Nelson, K., Siegler, A. J., Sullivan, P. S., Collins, M. H., Weitz, J. S., & Lopman, B. A. (2021) · Epidemiology · doi:10.1097/ede.0000000000001361 · Cited by 76
Patel, A. R., Walters, J. N., Reuschel, E. L., Schultheis, K., Parzych, E. M., Gary, E. N., Maricic, I., Purwar, M., Eblimit, Z., Walker, S. N., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100420 · Cited by 76
Sequence signatures of two public antibody clonotypes that bind SARS-CoV-2 receptor binding domain
Tan, T. J. C., Yuan, M., Kuzelka, K., Padron, G. C., Beal, J. R., Chen, X., Wang, Y., Rivera-Cardona, J., Zhu, X., Stadtmueller, B. M., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24123-7 · Cited by 75
Jangra, S., Vrieze, J. D., Choi, A., Rathnasinghe, R., Laghlali, G., Uvyn, A., Herck, S. V., Nuhn, L., Deswarte, K., Zhong, Z., et al. (2021) · Angewandte Chemie International Edition · doi:10.1002/anie.202015362 · Cited by 77
Self-citationCOVID-19: Seroprevalence and Vaccine Responses in UK Dental Care Professionals
Shields, A. M., Faustini, S. E., Kristunas, C., Cook, A. M., Backhouse, C., Dunbar, L., Ebanks, D., Emmanuel, B., Crouch, E., Kröger, A., et al. (2021) · Journal of Dental Research · doi:10.1177/00220345211020270 · Cited by 80
Kozlovskaya, L. I., Piniaeva, A. N., Ignatyev, G. M., Gordeychuk, I. V., Volok, V. P., Rogova, Y. V., Shishova, А. A., Kovpak, A. A., Ivin, Y. Y., Antonova, L. P., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1971569 · Cited by 76
Boonyaratanakornkit, J. B., Morishima, C., Selke, S., Zamora, D., McGuffin, S. A., Shapiro, A. E., Campbell, V. L., McClurkan, C. L., Jing, L., Gross, R., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci144930 · Cited by 74
Review on Up-to-Date Status of Candidate Vaccines for COVID-19 Disease
Belete, T. M. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s288877 · Cited by 74
SARS-CoV-2 variants and COVID-19 vaccines: Current challenges and future strategies
Gong, W., Parkkila, S., Wu, X., & Aspatwar, A. (2022) · International Reviews of Immunology · doi:10.1080/08830185.2022.2079642 · Cited by 75
Li, C., Yu, D., Wu, X. J., Hong, L., Zhou, Z., Xie, Y., Li, T., Wu, J., Lu, F., Feng, L. Z., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-24230-5 · Cited by 75
Serological follow-up of SARS-CoV-2 asymptomatic subjects
Milani, G. P., Dioni, L., Favero, C., Cantone, L., Macchi, C., Delbue, S., Bonzini, M., Montomoli, E., Bollati, V., Albetti, B., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-77125-8 · Cited by 74
Koerber, N., Priller, A., Yazici, S., Bauer, T., Cheng, C., Mijočević, H., Wintersteller, H., Jeske, S. D., Vogel, E., Feuerherd, M., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27649-y · Cited by 75
Endemic SARS-CoV-2 will maintain post-pandemic immunity
Veldhoen, M., & Simas, J. P. (2021) · Nature reviews. Immunology · doi:10.1038/s41577-020-00493-9 · Cited by 70
Qureshi, A. I., Baskett, W. I., Huang, W., Lobanova, I., Naqvi, S. H., & Shyu, C. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab345 · Cited by 70
Persistence of IgG response to SARS-CoV-2
Duysburgh, E., Mortgat, L., Barbezange, C., Dierick, K., Fischer, N., Heyndríckx, L., Hutse, V., Thomas, I., Gucht, S. V., Vuylsteke, B., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30943-9 · Cited by 68
Bertoletti, A., Tan, A. T., & Bert, N. L. (2021) · Oxford Open Immunology · doi:10.1093/oxfimm/iqab006 · Cited by 69
SARS-CoV-2 infection incidence during the first and second COVID-19 waves in Italy
Vinceti, M., Filippini, T., Rothman, K. J., Federico, S. D., & Orsini, N. (2021) · Environmental Research · doi:10.1016/j.envres.2021.111097 · Cited by 73
Gevertz, J. L., Greene, J. M., Sanchez‐Tapia, C., & Sontag, E. D. (2020) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2020.110539 · Cited by 67
The Prevalence of Antibodies to SARS-CoV-2 Among Blood Donors in China
Chang, L., Hou, W., Zhao, L., Zhang, Y., Wang, Y., Wu, L., Xu, T., Wang, L., Wang, J., Ma, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-021-21503-x · Cited by 68
Terpos, E., Stellas, D., Rosati, M., Sergentanis, T. Ν., Hu, X., Politou, M., Pappa, V., Ntanasis‐Stathopoulos, I., Karaliota, S., Bear, J., et al. (2021) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2021.05.010 · Cited by 68
Long COVID: Clinical characteristics, proposed pathogenesis and potential therapeutic targets
Kenny, G., Townsend, L., Savinelli, S., & Mallon, P. W. G. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1157651 · Cited by 72
Feng, Y., Zhang, Y., He, Z., Huang, H., Tian, X., Wang, G., Chen, D., Ren, Y., Jia, L., Wang, W., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.101226 · Cited by 65
Harrington, W. E., Trakhimets, O., Andrade, D. V., Dambrauskas, N., Raappana, A., Jiang, Y., Houck, J., Selman, W., Yang, A., Vigdorovich, V. I., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100253 · Cited by 65
Naturally Acquired SARS-CoV-2 Immunity Persists for Up to 11 Months Following Infection
Giorgi, V. D., West, K. A., Henning, A. N., Chen, L. N., Holbrook, M. R., Gross, R., Liang, J. Y., Postnikova, E. N., Trenbeath, J. L., Pogue, S., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab295 · Cited by 65
Gattinger, P., Niespodziana, K., Stiasny, K., Sahanic, S., Tulaeva, I., Borochova, K., Dorofeeva, Y., Schlederer, T., Sonnweber, T., Höfer, G., et al. (2021) · Allergy · doi:10.1111/all.15066 · Cited by 64
Guo, M., Shang, S., Li, M., Cai, G., Li, P., Chen, X., & Li, Q. (2024) · Medical Review · doi:10.1515/mr-2024-0013 · Cited by 64
Disease Severity, Fever, Age, and Sex Correlate With SARS-CoV-2 Neutralizing Antibody Responses
Schlickeiser, S., Schwarz, T., Steiner, S., Wittke, K., Besher, N. A., Meyer, O. G. J., Kalus, U. J., Prüß, A., Kurth, F., Zöller, T., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.628971 · Cited by 64
Khairallah, P., Aggarwal, N., Awan, A. A., Vangala, C., Airy, M., Pan, J. S.-C., Murthy, B. V. R., Winkelmayer, W. C., & Ramanathan, V. (2021) · Transplant International · doi:10.1111/tri.13840 · Cited by 65
Instructing durable humoral immunity for COVID-19 and other vaccinable diseases
Bhattacharya, D. (2022) · Immunity · doi:10.1016/j.immuni.2022.05.004 · Cited by 64
SARS-CoV-2 Serologic Assay Needs for the Next Phase of the US COVID-19 Pandemic Response
Gundlapalli, A. V., Salerno, R. M., Brooks, J. T., Averhoff, F. M., Petersen, L. R., McDonald, L. C., Iademarco, M. F., Response, C. C.-1., Carroll, Y. I., Gorwitz, R. J., et al. (2020) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofaa555 · Cited by 63
Havervall, S., Ng, H., Falk, A. J., Greilert‐Norin, N., Månberg, A., Marking, U. W., Laurén, I., Gabrielsson, L., Salomonsson, A., Aguilera, K., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13387 · Cited by 63
Ozonoff, A., Schaenman, J. M. D., Jayavelu, N. D., Milliren, C. E., Calfee, C. S., Cairns, C. B., Kraft, M., Baden, L. R., Shaw, A. C., Krammer, F., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104208 · Cited by 65
Self-citationCOVID-19: Immunology, Immunopathogenesis and Potential Therapies
Bhardwaj, A., Sapra, L., Saini, C., Azam, Z., Mishra, P. K., Verma, B., Mishra, G. C., & Srivastava, R. K. (2021) · International Reviews of Immunology · doi:10.1080/08830185.2021.1883600 · Cited by 65
Zhao, H., Wang, T.-C., Li, X.-F., Zhang, N.-N., Li, L., Zhou, C., Deng, Y.-Q., Cao, T.-S., Yang, G., Li, R.-T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00861-4 · Cited by 60
Manisty, C., Treibel, T. A., Jensen, M. P., Semper, A. E., Joy, G., Gupta, R. K., Cutiño‐Moguel, T., Andiapen, M., Jones, J., Taylor, S. C., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103259 · Cited by 60
Haynes, W. A., Kamath, K., Bozekowski, J. D., Baum, E., Campbell, M., Casanovas‐Massana, A., Daugherty, P. S., Cruz, C. S. D., Dhal, A., Farhadian, S., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02835-2 · Cited by 60
Anti-SARS-CoV-2 antibodies elicited by COVID-19 mRNA vaccine exhibit a unique glycosylation pattern
Farkash, I., Feferman, T., Saban, N. C., Avraham, Y., Morgenstern, D., Mayuni, G., Barth, N., Lustig, Y., Miller, L., Shouval, D. S., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110114 · Cited by 60
Mao, Y., Wang, W., Ma, J., Wu, S., & Sun, F. (2021) · Chinese Medical Journal · doi:10.1097/cm9.0000000000001892 · Cited by 60
Peghin, M., Martino, M. D., Fabris, M., Palese, A., Visintini, E., Graziano, E., Gerussi, V., Bontempo, G., D’Aurizio, F., Biasotto, A., et al. (2021) · Journal of Clinical Microbiology · doi:10.1128/jcm.01138-21 · Cited by 61
Dobaño, C., Ramírez‐Morros, A., Alonso, S., Vidal‐Alaball, J., Ruiz‐Olalla, G., Vidal, M., Rubio, R., Cascant, E., Parras, D., Melero, N. R., et al. (2021) · BMC Medicine · doi:10.1186/s12916-021-02032-2 · Cited by 58
Trougakos, I. P., Terpos, E., Zirou, C., Sklirou, A. D., Apostolakou, F., Gumeni, S., Charitaki, I., Papanagnou, E., Bagratuni, T., Liacos, C., et al. (2021) · BMC Medicine · doi:10.1186/s12916-021-02090-6 · Cited by 60
Impact of rituximab on COVID-19 outcomes
Levavi, H., Lancman, G., & Gabrilove, J. L. (2021) · Annals of Hematology · doi:10.1007/s00277-021-04662-1 · Cited by 58
The impact of vaccination on the spread of COVID-19: Studying by a mathematical model
Yang, B., Yu, Z., & Cai, Y. (2021) · Physica A Statistical Mechanics and its Applications · doi:10.1016/j.physa.2021.126717 · Cited by 63
Early Humoral Response Correlates with Disease Severity and Outcomes in COVID-19 Patients
Hashem, A. M., Algaissi, A. A., Almahboub, S. A., Alfaleh, M. A., Abujamel, T. S., Alamri, S. S., Alluhaybi, K. A., Hobani, H. I., Alharbi, R. H., Alsulaiman, R. M., et al. (2020) · Viruses · doi:10.3390/v12121390 · Cited by 58
Advances in Neutralization Assays for SARS‐CoV‐2
Lu, Y., Jin, W., Li, Q., Hu, H., Lu, J., & Chen, Z. (2021) · Scandinavian Journal of Immunology · doi:10.1111/sji.13088 · Cited by 58
Focosi, D., Maggi, F., Mazzetti, P., & Pistello, M. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2170 · Cited by 59
The evolutionary dynamics of endemic human coronaviruses
Jo, W. K., Drosten, C., & Drexler, J. F. (2021) · Virus Evolution · doi:10.1093/ve/veab020 · Cited by 60
High seroprevalence but short‐lived immune response to SARS‐CoV‐2 infection in Paris
Anna, F., Goyard, S., Lalanne, A. I., Névo, F., Gransagne, M., Souque, P., Louis, D., Gillon, V., Turbiez, I., Bidard, F., et al. (2020) · European Journal of Immunology · doi:10.1002/eji.202049058 · Cited by 58
Durability of Immunity to SARS-CoV-2 and Other Respiratory Viruses
Siggins, M. K., Thwaites, R. S., & Openshaw, P. (2021) · Trends in Microbiology · doi:10.1016/j.tim.2021.03.016 · Cited by 61
Shrwani, K. J., Sharma, R. S., Krishnan, M., Jones, T., Neto, M. M., Cantoni, D. M., Temperton, N. J., Dobson, S. L., Subramaniam, K. S., McNamara, P. S., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab333 · Cited by 58
Metadata
- Authors
- Wajnberg, A., Amanat, F., Firpo, A., Altman, D. R., Bailey, M. J., Mansour, M., McMahon, M., Meade, P., Mendu, D. R., Muellers, K., Stadlbauer, D., Stone, K., Strohmeier, S., Simon, V., Aberg, J., Reich, D. L., Krammer, F., & Cordon-Cardo, C.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- Clinical Microbiology Laboratory, Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA.
- Corresponding author
- Wajnberg, Ania
- Krammer, Florian
- ORCID
- Venue
- Science
- Published
- 2020-12-04
- Volume
- 370
- Issue
- 6521
- Pages
- 1227-1230
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC7810037
- OpenAlex
- W3094968263
- Cited by
- 1,195
- References
- 28
- Citations by year
- 2026: 16 · 2025: 46 · 2024: 50 · 2023: 117 · 2022: 280 · 2021: 594 · 2020: 92
- FWCI
- 35.39
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Science (publishedVersion, cc-by)
- medRxiv (acceptedVersion)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- ImmPort
- Funders
- National Institute of Allergy and Infectious Diseases (HHSN272201400008C, 75N93019C00051)
- JPB Foundation
- Open Philanthropy Project (#2020-215611)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
- Keywords
- SARS-CoV-2, COVID-19 pandemic, neutralizing antibodies, IgG, spike protein, antibody persistence, antibody titers, seroconversion, mild to moderate COVID-19
- MeSH terms
- COVID-19, SARS-CoV-2, Antibodies, Viral, Enzyme-Linked Immunosorbent Assay, Humans, Immunoglobulin G, Neutralization Tests, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
